BIOXYTRAN, INC
For the period ended Dec 31, 2024. Filed Apr 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 3, 2025
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Year endedDecember 31,2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to _____________
Commission file number:001-35027
(Exact name of registrant as specified in its charter)
| Nevada | 26-2797630 |
|---|---|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 75 2nd Ave., Ste 605, Needham, MA | 02494 |
|---|---|
| (Address of principal executive offices) | (Zip Code) |
617-454-1199
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:None
Securities registered pursuant to Section 12(g) of the Act:
Securities registered under Section 12(g) of the Exchange Act:
(Title of Class)
Common Stock, $.001 par value per share
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” and large “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
|---|---|---|---|
| Non-accelerated filer | ☒ | Smaller Reporting Company | ☒ |
| Emerging Growth Company | ☐ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☒
Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as at the latest practicable date.
| Class | Trading Symbol | Name of each exchange on which listed |
|---|---|---|
| Common Stock, $0.001 par value per share | BIXT | OTCQB |
As at June 30, 2024, the aggregate market value of the registrant’s voting stock held by non-affiliates based upon the per share closing price of $0.096 as reported on the OTCQB Market and the market value of shares owned by non-affiliates was approximately $8,002,442 (based on the assumption, solely for purposes of this computation, that all Directors and Officers of the registrant were affiliates of the registrant).
The number of shares of Common Stock outstanding as at April 3, 2025, was 88,881,858 shares.
FORM 10-K
TABLE OF CONTENTS
| PART I | |||
|---|---|---|---|
| Item 1 | Business | 1 | |
| Item 1A | Risk Factors | 12 | |
| Item 1B | Unresolved Staff Comments | 12 | |
| Item 1C | Cybersecurity Risk Management, Strategy, and Governance | 12 | |
| Item 2 | Properties | 14 | |
| Item 3 | Legal Proceedings | 14 | |
| Item 4 | Mine Safety Disclosures | 14 | |
| PART II | |||
| Item 5 | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 15 | |
| Item 6 | Selected Financial Data | 19 | |
| Item 7 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 20 | |
| Item 7A | Quantitative and Qualitative Disclosures About Market Risk | 26 | |
| Item 8 | Financial Statements and Supplementary Data | 26 | |
| Item 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosures | 26 | |
| Item 9A | Controls and Procedures | 26 | |
| Item 9B | Other Information | 27 | |
| PART III | |||
| Item 10 | Directors, Executive Officers and Corporate Governance | 28 | |
| Item 11 | Executive Compensation | 32 | |
| Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 34 | |
| Item 13 | Certain Relationships and Related Transactions, and Director Independence | 35 | |
| Item 14 | Principal Accounting Fees and Services | 35 | |
| PART IV | |||
| Item 15 | Exhibits and Financial Statement Schedules | 37 | |
| SIGNATURES | 43 | ||
| FINANCIAL STATEMENTS AND FOOTNOTES | F-1 - F-24 | ||
i
Special Note Regarding Forward Looking Statements
This Annual Report on Form 10-K contains a number of “forward-looking statements”. Specifically, all statements other than statements of historical facts included in this Annual Report on Form 10-K regarding our financial position, business strategy and plans and objectives of management for future operations are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this Annual Report on Form 10-K and the documents incorporated by reference herein, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “continue” and “intend,” and words or phrases of similar import, as they relate to our financial position, business strategy and plans, or objectives of management, are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors.
You should understand that the following important factors, in addition to those discussed in our periodic reports to be filed with the SEC under the Exchange Act, could affect our future results and could cause those results to differ materially from those expressed in such forward-looking statements:
| ● | We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. |
| ● | We are a company with limited operating history which makes it difficult to evaluate our current business and future prospects. |
| ● | We will require additional financing to implement our business plan which may not be available on favorable terms or at all, and we may have to accept financing terms that would adversely affect our stockholders. |
| ● | Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates and dietary supplements. |
| ● | Our products are based on novel, unproven technologies. |
| ● | Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. |
| ● | We may be unable to commercialize our drug candidates |
| ● | Our success depends upon our ability to retain key executives and to attract, retain, and motivate qualified personnel and direction and the loss of these persons could adversely affect our operations and results. |
| ● | We will need regulatory approvals to commercialize our products as drugs. |
| ● | Our competitive position depends on protection of our intellectual property. |
| ● | The market for our proposed products is rapidly changing and competitive, and new drugs and new treatments which may be developed by others could impair our ability to maintain and grow our business and remain competitive. |
| ● | We may become involved in lawsuits to protect or enforce patents that may issue to us, that we may acquire, or may license in the future, or other intellectual property, which could be expensive, time-consuming and ultimately unsuccessful. |
| ● | As a public company, we must implement additional and expensive finance and accounting systems, procedures and controls as we grow our business and organization to satisfy new reporting requirements, which will increase our costs and require additional management resources. |
Although we believe that our expectations (including those on which our forward-looking statements are based) are reasonable, we cannot assure you that those expectations will prove to be correct. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described in our forward-looking statements as anticipated, believed, estimated, expected or intended.
Except for our ongoing obligations to disclose material information under the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or any other reason. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this Annual Report on Form 10-K and the documents incorporated by reference herein might not occur.
ii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.